Abstract Objective To synthesize the current preclinical and clinical evidence on the utility and potential mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a therapeutic strategy for major ophthalmic diseases, including diabetic retinopathy, glaucoma, and age-related macular degeneration
So the number of people who would receive a treatment is small
Dose Comparison for Different Goals Maximum Weight Loss Dose: 8-12 mg weekly Rationale: Strongest appetite suppression and metabolic effects Body Recomposition Dose: 4-8 mg weekly Rationale: Balance of metabolic benefits with manageable appetite Lean Bulking Dose: 2-4 mg weekly Rationale: Metabolic support with minimal appetite interference Maintenance Dose: 2-4 mg weekly Rationale: Sustain improvements with low side effect burden Lower doses in the 2-4 mg range provide meaningful metabolic benefits including improved insulin sensitivity, enhanced fat oxidation, and better nutrient partitioning without the profound appetite suppression that makes eating adequate calories difficult
A survey by benefits consultant Mercer found 49% of large employers covered GLP-1 medications for obesity in 2025, up from 41% in 2023
IV delivery bypasses the digestive system, ensuring nutrients are available at higher concentrations right away
This plan will work to achieve your goals
